These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 12557699)

  • 1. [Clinical problems of systematic prostate needle biopsy in the detection of prostate cancer].
    Suzuki H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):16-20. PubMed ID: 12557699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.
    Pelzer A; Bektic J; Berger AP; Pallwein L; Halpern EJ; Horninger W; Bartsch G; Frauscher F
    J Urol; 2005 Jun; 173(6):1926-9. PubMed ID: 15879783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection.
    Canto EI; Singh H; Shariat SF; Kadmon D; Miles BJ; Wheeler TM; Slawin KM
    J Urol; 2004 Sep; 172(3):900-4. PubMed ID: 15310993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels.
    Yang JC; Tang J; Li J; Luo Y; Li Y; Shi H
    Acad Radiol; 2008 Oct; 15(10):1291-7. PubMed ID: 18790401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with low prostate-specific antigen levels (< or =4 ng/ml) would benefit from a twelve-core biopsy protocol for prostate cancer detection.
    Thiesler T; Trinkler F; Horcic M; Willi N; Cathomas G; Hailemariam S
    Urol Int; 2007; 78(4):318-22. PubMed ID: 17495489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?
    Anast JW; Andriole GL; Bismar TA; Yan Y; Humphrey PA
    Urology; 2004 Sep; 64(3):544-50. PubMed ID: 15351590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 10. [Analysis of transrectal needle biopsy of the prostate: usefulness of systematic 12 core biopsy].
    Imazu T; Yokoyama S; Fukuhara S; Hara T; Yamaguchi S; Adachi S
    Hinyokika Kiyo; 2007 Jun; 53(6):365-8. PubMed ID: 17628932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical impact of body mass index on prostate biopsy in patients with intermediate PSA levels].
    Sekita N; Suzuki H; Kamijima S; Chini K; Fujimura M; Mikami K
    Hinyokika Kiyo; 2008 Jul; 54(7):479-83. PubMed ID: 18697492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
    Johnson L
    Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: a multivariate analysis model.
    Abdel-Khalek M; El-Baz M; Ibrahiem el-H
    BJU Int; 2004 Sep; 94(4):528-33. PubMed ID: 15329106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
    Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
    Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
    J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased detection of clinically significant prostate cancer by additional sampling from the anterior lateral horns of the peripheral zone in combination with the standard sextant biopsy.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2004 Jun; 11(6):402-6. PubMed ID: 15157210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proportion of cores with high-grade prostatic intraepithelial neoplasia on extended-pattern needle biopsy is significantly associated with prostate cancer on site-directed repeat biopsy.
    Akhavan A; Keith JD; Bastacky SI; Cai C; Wang Y; Nelson JB
    BJU Int; 2007 Apr; 99(4):765-9. PubMed ID: 17378840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies.
    Montironi R; Mazzuccheli R; Scarpelli M; Lopez-Beltran A; Fellegara G; Algaba F
    BJU Int; 2005 Jun; 95(8):1146-52. PubMed ID: 15877724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.